Efficacy Study of Hydroxychloroquine to Treat High-risk Coronary Artery Disease.

Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography.

The purpose of this study is to evaluate whether treated with hydroxychloroquine could improve therapeutic effect for patients with high-risk coronary artery disease.

This double blind, placebo, randomized controlled trial is going to assess if hydroxychloroquine could improve the high sensitivity C-reaction protein, blood lipid, blood glucose and blood pressure, also whether hydroxychloroquine could affect the secretion of inflammatory cytokines and the M1/M2 phenotype polarization of macrophages in patients with high-risk coronary artery disease.

Inclusion Criteria:

• Patients have been diagnosed coronary artery disease by coronary angiography or CT angiography.
• coronary artery disease with hypertension or diabetes or hyperlipidaemia(LDL>1.8mmol/L)
• High sensitivity C-reactive protein >1mg/L.
• On guideline-based secondary prevention of coronary heart disease medications≥1 months.
• No use of steroids, antibiotics, immunosuppressors a week before treatment.

Exclusion Criteria:

• Retinal disease.
• Chronic hepatopathy(ALT>120U/L).
• Renal dysfunction (eGFR<60).
• Moderately severe anemia, thrombocytopenia and leukocytopenia.
• Other contraindications for hydroxychloroquine.
• Active hemorrhage.
• Cancer or life expectancy< a year.
• New York Heart Association (NYHA) functional class≥class III, Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting in plan.
• Pregnancy and lactation.